Aptalis Pharma Canada Inc.

Aptalis Pharma Canada Ulc

Hugues Moreau

David Powell

Carl Gauthier

Yves Dumoulin

The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP &#x3c;616&#x3e;) and a hard fat having an ascending melting point of 32 to 35.5&#xb0; C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m/g to about 2.8 m/g (e.g., from about 0.1 m/g to about 1.3 m/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40&#xb0; C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.

Growing community of inventors

Luce, France

Hugues Moreau